Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 49

1.

Effect of glatiramer acetate on peripheral blood brain-derived neurotrophic factor and phosphorylated TrkB levels in relapsing-remitting multiple sclerosis.

Vacaras V, Major ZZ, Muresanu DF, Krausz TL, Marginean I, Buzoianu DA.

CNS Neurol Disord Drug Targets. 2014;13(4):647-51.

PMID:
24938775
[PubMed - in process]
2.

Cerebrovascular Profile Assessment in Parkinson's Disease Patients.

Perju-Dumbrava L, Muntean ML, Mureşanu DF.

CNS Neurol Disord Drug Targets. 2014 Jun 18. [Epub ahead of print]

PMID:
24938774
[PubMed - as supplied by publisher]
3.

The role of functionalized magnetic iron oxide nanoparticles in the central nervous system injury and repair: new potentials for neuroprotection with Cerebrolysin therapy.

Sharma HS, Menon PK, Lafuente JV, Aguilar ZP, Wang YA, Muresanu DF, Mössler H, Patnaik R, Sharma A.

J Nanosci Nanotechnol. 2014 Jan;14(1):577-95. Review.

PMID:
24730284
[PubMed - indexed for MEDLINE]
4.

The vascular component of Alzheimer's disease.

Muresanu DF, Popa-Wagner A, Stan A, Buga AM, Popescu BO.

Curr Neurovasc Res. 2014 May;11(2):168-76.

PMID:
24712646
[PubMed - in process]
5.

Disease activity and disability evolution under glatiramer acetate: a clinical approach.

Vacaras V, Major ZZ, Seewooram R, Major KA, Muresanu DF, Buzoianu AD.

Neuropsychopharmacol Hung. 2014 Mar;16(1):11-8.

PMID:
24687014
[PubMed - indexed for MEDLINE]
Free Article
6.

Conscience and consciousness: a definition.

Vithoulkas G, Muresanu DF.

J Med Life. 2014 Mar 15;7(1):104-8. Epub 2014 Mar 25.

PMID:
24653768
[PubMed - in process]
Free PMC Article
7.

Conference report: 13th International Congress on Amino Acids, Peptides and Proteins (ICAPP); Neurobiology Symposium, October 5-7, 2013; Galveston TX, USA.

Sharma H, Muresanu DF, Sharma A.

CNS Neurol Disord Drug Targets. 2014 Feb;13(1):2-3. No abstract available.

PMID:
24533926
[PubMed - in process]
8.

Two novel HTRA1 mutations in a European CARASIL patient.

Bianchi S, Di Palma C, Gallus GN, Taglia I, Poggiani A, Rosini F, Rufa A, Muresanu DF, Cerase A, Dotti MT, Federico A.

Neurology. 2014 Mar 11;82(10):898-900. doi: 10.1212/WNL.0000000000000202. Epub 2014 Feb 5. No abstract available.

PMID:
24500651
[PubMed - indexed for MEDLINE]
9.

Characterization of CD4+ and CD8+ Tregs in a Hodgkin's lymphoma patient presenting with myasthenia-like symptoms.

Krausz LT, Major ZZ, Muresanu DF, Chelaru E, Nocentini G, Riccardi C.

Ideggyogy Sz. 2013 Sep 30;66(9-10):343-8.

PMID:
24358691
[PubMed - indexed for MEDLINE]
10.

Novel therapeutic strategies using nanodrug delivery, stem cells and combination therapy for CNS trauma and neurodegenerative disorders.

Sharma HS, Muresanu DF, Sharma A.

Expert Rev Neurother. 2013 Oct;13(10):1085-8. doi: 10.1586/14737175.2013.836297. Epub 2013 Oct 3.

PMID:
24089700
[PubMed - indexed for MEDLINE]
11.

Cerebrovascular profile assessment in Parkinson's disease patients.

Perju-Dumbravă L, Muntean ML, Muresanu DF.

CNS Neurol Disord Drug Targets. 2014;13(4):712-7.

PMID:
24040791
[PubMed - in process]
12.

Exacerbation of brain pathology after partial restraint in hypertensive rats following SiO₂ nanoparticles exposure at high ambient temperature.

Sharma HS, Muresanu DF, Patnaik R, Sharma A.

Mol Neurobiol. 2013 Oct;48(2):368-79. doi: 10.1007/s12035-013-8502-y. Epub 2013 Jul 6.

PMID:
23832531
[PubMed - indexed for MEDLINE]
13.

Size- and age-dependent neurotoxicity of engineered metal nanoparticles in rats.

Sharma A, Muresanu DF, Patnaik R, Sharma HS.

Mol Neurobiol. 2013 Oct;48(2):386-96. doi: 10.1007/s12035-013-8500-0. Epub 2013 Jul 3.

PMID:
23821031
[PubMed - indexed for MEDLINE]
14.

Clinical improvement and cortical adaptations after functional electrical stimulation in Parkinson's disease patients.

Popa L, Constantinescu A, Mureşanu DF, Irimie A, Bălănescu NR, Popescu CD.

CNS Neurol Disord Drug Targets. 2013 Mar;12(2):265-73.

PMID:
23469843
[PubMed - indexed for MEDLINE]
15.

Stroke care in Central Eastern Europe: current problems and call for action.

Lenti L, Brainin M, Titianova E, Morovic S, Demarin V, Kalvach P, Skoloudik D, Kobayashi A, Czlonkowska A, Muresanu DF, Shekhovtsova K, Skvortsova VI, Sternic N, Beslac Bumbasirevic L, Svigelj V, Turcani P, Bereczki D, Csiba L.

Int J Stroke. 2013 Jul;8(5):365-71. doi: 10.1111/j.1747-4949.2012.00845.x. Epub 2012 Sep 13.

PMID:
22974486
[PubMed - indexed for MEDLINE]
16.

Pleiotropic neuroprotective and metabolic effects of Actovegin's mode of action.

Machicao F, Muresanu DF, Hundsberger H, Pflüger M, Guekht A.

J Neurol Sci. 2012 Nov 15;322(1-2):222-7. doi: 10.1016/j.jns.2012.07.069. Epub 2012 Aug 19. Review.

PMID:
22910148
[PubMed - indexed for MEDLINE]
17.

Analysis of CYP2C9*2, CYP2C9*3 and VKORC1 -1639 G>A polymorphisms in a population from South-Eastern Europe.

Buzoianu AD, Trifa AP, Mureşanu DF, Crişan S.

J Cell Mol Med. 2012 Dec;16(12):2919-24. doi: 10.1111/j.1582-4934.2012.01606.x.

PMID:
22863573
[PubMed - indexed for MEDLINE]
18.

Towards a roadmap in brain protection and recovery.

Muresanu DF, Buzoianu A, Florian SI, von Wild T.

J Cell Mol Med. 2012 Dec;16(12):2861-71. doi: 10.1111/j.1582-4934.2012.01605.x. Review.

PMID:
22863521
[PubMed - indexed for MEDLINE]
19.

Neuroprotective effects of cerebrolysin, a combination of different active fragments of neurotrophic factors and peptides on the whole body hyperthermia-induced neurotoxicity: modulatory roles of co-morbidity factors and nanoparticle intoxication.

Sharma HS, Sharma A, Mössler H, Muresanu DF.

Int Rev Neurobiol. 2012;102:249-76. doi: 10.1016/B978-0-12-386986-9.00010-7. Review.

PMID:
22748833
[PubMed - indexed for MEDLINE]
20.

Quercetin in hypoxia-induced oxidative stress: novel target for neuroprotection.

Pandey AK, Patnaik R, Muresanu DF, Sharma A, Sharma HS.

Int Rev Neurobiol. 2012;102:107-46. doi: 10.1016/B978-0-12-386986-9.00005-3. Review.

PMID:
22748828
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk